Antithrombotics - Reaching the untreated prophylaxis market

Novel oral anticoagulants and antiplatelet agents will have a profound impact on the antithrombotics market. Datamonitor expects Bayer's rivaroxaban and Sankyo/Eli Lilly's prasugrel to achieve blockbuster status. Parenteral anticoagulants are not expected to be large revenue generators, due to low clinical unmet need in this market segment and strong competition from current gold standard agents.

Following the abrupt withdrawal of AstraZeneca's Exanta in February 2006, Bayer Healthcare's rivaroxaban and Boehringer Ingelheim's Rendix are well positioned to profit from patients switching from warfarin, and market growth obtained by recruiting the previously untreated population.

The highest selling brands in the antidiabetics market are Lovenox (enoxaparin) and Plavix (clopidogrel), but these agents will be genericized within our forecast period. Consequently, pipeline agents are expected to become significant drivers in the market.

Acute Coronary Syndrome is usually the first indication for which novel anticoagulants are approved; this is a quick route to market, while drug companies then prepare to launch their products in more lucrative, chronic treatment markets.

Read more...

• Restricted Drug Distribution (02/06/2008)
• Antithrombotics (27/05/2008)
• Antithrombotics (19/05/2008)

• Dyslipidemia (21/05/2008)
• Insomnia (21/05/2008)
• Fibromyalgia (21/05/2008)
• Canadian Generics Market (21/05/2008)
• Female Sexual Dysfunction (21/05/2008)
• Supportive Care in Oncology (21/05/2008)
• Irritable Bowel Syndrome (21/05/2008)
• Monoclonal Antibodies (21/05/2008)
• Depression (21/05/2008)

---